Neil E. Fleshner - Jun 30, 2021 Form 4 Insider Report for POINT Biopharma Global Inc. (PNT)

Role
Chief Medical Officer, Director
Signature
William L. Demers, by Power of Attorney for Neil E. Fleshner
Stock symbol
PNT
Transactions as of
Jun 30, 2021
Transactions value $
$0
Form type
4
Date filed
6/30/2021, 09:27 PM
Next filing
Jul 8, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PNT Common Stock Award +3.59M 3.59M Jun 30, 2021 Direct F1
transaction PNT Common Stock Award +233K 233K Jun 30, 2021 1510789 Ontario Inc. F1, F2
transaction PNT Common Stock Award +358 358 Jun 30, 2021 Trust Controlled by Wife F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 30, 2021, POINT BIOPHARMA GLOBAL INC. (f/k/a Therapeutics Acquisition Corp., the "Issuer") consummated a business combination (the "Business Combination") pursuant to which RACA, Bodhi Merger Sub, Inc., a wholly-owned subsidiary of the Issuer merged with and into POINT Biopharma Inc., ("Old POINT"). At the effective time of the Business Combination, each share of Old POINT outstanding as of immediately prior to the effective time was exchanged for shares of Common Stock of the Issuer based on an implied Old POINT vested equity value of $585,000,000. As a result, the Reporting Person received the reported shares of the Issuer's Common Stock in consideration for the equity securities of Old POINT held by the Reporting Person prior to the Business Combination.
F2 A corporation controlled by Reporting Person
F3 A trust, whose trustee is the Reporting Person's spouse.